10 results on '"Byung Jo Jeon"'
Search Results
2. A Novel Technique of Morcellation Using a Pneumovesicum After Holmium Laser Enucleation of the Prostate in Complicated Situations: Our Initial Experience and Tips
- Author
-
Jae Young Park, Hoon Choi, Byung Jo Jeon, Bum Sik Tae, and Jae Hyun Bae
- Subjects
Novel technique ,medicine.medical_specialty ,Adenoma ,Urethral stricture ,Urology ,Enucleation ,030232 urology & nephrology ,Holmium laser ,Subgroup analysis ,Morcellation ,lcsh:RC870-923 ,03 medical and health sciences ,Holmium ,0302 clinical medicine ,Prostate ,medicine ,Clinical Investigation ,030219 obstetrics & reproductive medicine ,business.industry ,Pneumovesicum ,medicine.disease ,lcsh:Diseases of the genitourinary system. Urology ,Surgery ,medicine.anatomical_structure ,Neurology ,Original Article ,Neurology (clinical) ,Morcellator ,business ,Prostatic hyperplasia - Abstract
Purpose To describe our initial experience with a novel method of adenoma retrieval using a pneumovesicum (PNV) after Holmium laser enucleation of the prostate (HoLEP). Methods From January 2016 to April 2018, a total of 93 consecutive patients treated with HoLEP were enrolled in this study. For tissue morcellation, we used the PNV morcellation technique for an initial series of 21 patients and the conventional technique (Lumenis VersaCut) for a consecutive series of 72 patients. We compared efficiency and safety between the novel technique and the traditional technique. Subgroup analysis was performed to assess the effectiveness of the current technique in the large prostate (>70 mL). Results There were significant differences in mean age and prostate volume between the 2 groups. However, there were no significant differences in the baseline characteristics and preoperative parameters in the subgroup analysis of large prostates (>70 mL). The mean morcellation efficiency was higher (8.50±1.94 minutes vs. 1.76±0.45 minutes, P
- Published
- 2019
3. Does mirabegron relieve ureteric stent-related discomfort? A prospective, randomized, multicentre study
- Author
-
Byung Jo Jeon, Keon-Cheol Lee, Bum Sik Tae, Sung Yong Cho, Jae Hyun Bae, Jae Young Park, Seok Cho, and Hoon Choi
- Subjects
Adult ,Male ,medicine.medical_specialty ,Ureteral Calculi ,Urology ,Urinary system ,medicine.medical_treatment ,030232 urology & nephrology ,law.invention ,03 medical and health sciences ,0302 clinical medicine ,Randomized controlled trial ,law ,Humans ,Medicine ,Prospective Studies ,Ureteric stent ,Aged ,Pain, Postoperative ,business.industry ,Stent ,Middle Aged ,Thiazoles ,Treatment Outcome ,030220 oncology & carcinogenesis ,Urological Agents ,Acetanilides ,Female ,Stents ,International Prostate Symptom Score ,General health ,Ureter ,business ,Mirabegron ,Symptom score ,medicine.drug - Abstract
Objectives To evaluate the effects of 50 mg mirabegron once daily for ureteric stent-related discomfort after ureteroscopic procedures by conducting a multicentre randomized study. Patients and methods A total of 100 patients with indwelling ureteric stents after ureteroscopic stone removal or retrograde intrarenal surgery (RIRS) were randomized 1:1 to receive either no treatment or mirabegron during the stenting period. At the time of stent removal, the validated Ureteral Stent Symptom Questionnaire (USSQ), International Prostate Symptom Score (IPSS), total amount of analgesics administered, and post-voiding residual urine volume were reported for each patient. Results Overall, 96 patients were enrolled for analysis. The postoperative USSQ body pain score (21.96 vs 13.96; P = 0.007) and overall pain score (5.58 vs 2.83; P = 0.002) were lower in the mirabegron group than in the control group. The USSQ urinary symptom scores (32.58 vs 27.92; P = 0.582) and USSQ general health score (17.71 vs 14.00; P = 0.281) were also lower in the mirabegron group, but the difference was not significant. Postoperative IPSS total scores and quality-of-life scores were lower in the mirabegron group, but the difference was not significant. The change in IPSS storage symptom score, however, was lower in the mirabegron group than in the control group (3.58 ± 3.58 vs 1.83 ± 4.39; P = 0.035). Post-void residual urine volume did not differ between the two groups (P > 0.05). Conclusion The use of 50 mg mirabegron once daily has the potential to reduce ureteric stent-related discomfort. Prospective larger-scale, placebo-controlled studies are warranted to further evaluate the beneficial effects of mirabegron on stent-related symptoms.
- Published
- 2018
- Full Text
- View/download PDF
4. Correlation of Androgen Deprivation Therapy with Cognitive Dysfunction in Patients with Prostate Cancer: A Nationwide Population-Based Study Using the National Health Insurance Service Database
- Author
-
Bum Sik Tae, Seung Hun Shin, Byung Jo Jeon, Hoon Choi, Jae Young Park, and Jae Hyun Bae
- Subjects
0301 basic medicine ,Male ,Cancer Research ,Databases, Factual ,National Health Programs ,Population ,Prostate neoplasm ,Comorbidity ,Kaplan-Meier Estimate ,Androgen deprivation therapy ,computer.software_genre ,Risk Assessment ,03 medical and health sciences ,Prostate cancer ,0302 clinical medicine ,Cognitive dysfunction ,Risk Factors ,Republic of Korea ,medicine ,Dementia ,Humans ,Public Health Surveillance ,Prospective cohort study ,education ,Aged ,Proportional Hazards Models ,Aged, 80 and over ,education.field_of_study ,Database ,business.industry ,Hazard ratio ,Prostatic Neoplasms ,Androgen Antagonists ,Middle Aged ,medicine.disease ,Patient Outcome Assessment ,030104 developmental biology ,Oncology ,Nationwide population-based study ,030220 oncology & carcinogenesis ,Cohort ,Original Article ,business ,computer ,Follow-Up Studies - Abstract
Purpose The purpose of this study was to evaluate the association of androgen deprivation therapy (ADT) with cognitive dysfunction. Materials and methods Using the National Health Insurance Service database of the entire Korean adult prostate cancer population (n=236,391), data on ADT and cognitive dysfunction between 2008 and 2015 were analyzed. We excluded patients previously diagnosed with cognitive dysfunction, dementia, or a cerebral event history. We tested the effect of ADT on the risk of cognitive dysfunction using propensity score-matched Cox proportional hazards regression models and Kaplan-Meier survival analysis. Our final cohort comprised of 35,401 individuals with prostate cancer, including 24,567 men (70.6%) who underwent ADT. Results During a mean follow-up period of 4.1 years, 4,741 patients were newly diagnosed with cognitive dysfunction. A statistically significant association was found between ADT and the risk of cognitive dysfunction (hazard ratio, 1.169; p=0.002). Meanwhile, age (≥ 70 years), diabetes, hypertension, cardiovascular history, and peripheral vascular disease were identified as factors that contribute to the increased risk of cognitive dysfunction. In contrast, the use of statins and aspirin was associated with a lower risk of cognitive dysfunction. Kaplan-Meier analysis demonstrated that patients aged 70 years or older who underwent ADT had the lowest cumulative probability of remaining cognitive dysfunction-free (log-rank p Conclusion Our. Results revealed an association between the use of ADT for the treatment of prostate cancer and an increased risk of cognitive dysfunction in a nationwide population-based study. This finding should be further evaluated in prospective studies.
- Published
- 2018
5. PD19-03 CORRELATION OF ALPHA BLOCKER WITH DEMENTIA IN PATIENTS WITH BENIGN PROSTATE HYPERPLASIA: A NATIONWIDE POPULATION-BASED STUDY USING THE NATIONAL HEALTH INSURANCE SERVICE DATABASE
- Author
-
Tae Bum Sik, Byung Jo Jeon, Jae Young Park, Hong Chung, Hoon Choi, Bae Jae Hyun, and Sung Tae Cho
- Subjects
Service (business) ,medicine.medical_specialty ,business.industry ,Urology ,Hyperplasia ,urologic and male genital diseases ,medicine.disease ,Population based study ,National health insurance ,Internal medicine ,medicine ,Dementia ,In patient ,Alpha blocker ,business ,Benign prostate - Abstract
INTRODUCTION AND OBJECTIVES:To evaluate the association between alpha-blockers and dementia in patients with benign prostate hyperplasia (BPH).METHODS:Using the National Health Insurance Service da...
- Published
- 2019
- Full Text
- View/download PDF
6. PD30-11 CORRELATION OF ANDROGEN DEPRIVATION THERAPY WITH COGNITIVE DYSFUNCTION IN PATIENTS WITH PROSTATE CANCER: A NATIONWIDE POPULATION-BASED STUDY USING THE NATIONAL HEALTH INSURANCE SERVICE DATABASE
- Author
-
Tae Bum Sik, Jae Young Park, Byung Jo Jeon, Hong Chung, Hoon Choi, and Bae Jae Hyun
- Subjects
Gerontology ,Service (business) ,business.industry ,Urology ,Cognition ,medicine.disease ,Androgen deprivation therapy ,Correlation ,Population based study ,Prostate cancer ,National health insurance ,Medicine ,In patient ,business - Published
- 2019
- Full Text
- View/download PDF
7. PD17-09 CAN MIRABEGRON RELIEVE DOUBLE-J STENT-RELATED DISCOMFORT: A MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY
- Author
-
Jae Hyun Bae, Jae Young Park, Jong Bo Choi, Sung Tae Cho, Seok Cho, Hoon Choi, Jeong Gu Lee, BumSik Tae, Byung Jo Jeon, and Ji Sung Shim
- Subjects
medicine.medical_specialty ,Open label study ,business.industry ,Urology ,Double j stent ,medicine ,business ,Mirabegron ,Surgery ,medicine.drug - Published
- 2018
- Full Text
- View/download PDF
8. Comparison of open and pneumovesical approaches for Politano-Leadbetter ureteric reimplantation: a single-center long-term follow-up study
- Author
-
Jae Young Park, Hak Jong Choi, Bum Sik Tae, Jungdon Bae, and Byung Jo Jeon
- Subjects
Male ,medicine.medical_specialty ,Time Factors ,Long term follow up ,Urology ,Operative Time ,Urinary Bladder ,030232 urology & nephrology ,Single Center ,Vesicoureteral reflux ,03 medical and health sciences ,0302 clinical medicine ,030225 pediatrics ,medicine ,Humans ,Child ,Laparoscopy ,Ureteric reimplantation ,Retrospective Studies ,Vesico-Ureteral Reflux ,medicine.diagnostic_test ,business.industry ,medicine.disease ,Surgery ,Treatment Outcome ,Dimercaptosuccinic acid ,Child, Preschool ,Replantation ,Pediatrics, Perinatology and Child Health ,Urologic Surgical Procedures ,Female ,Ureter ,Complication ,business ,Ureteral reimplantation ,Follow-Up Studies ,medicine.drug - Abstract
Summary Purpose To report our experience with the laparoscopic pneumovesical approach for Politano-Leadbetter ureteric reimplantation and to compare the results to those obtained using a traditional open approach. Methods We retrospectively reviewed the medical records of 52 patients who underwent Politano-Leadbetter ureteral reimplantation between 2012 and 2017. The peri-operative parameters, postoperative outcomes, and complication rates of patients who underwent the open approach for the Politano-Leadbetter procedure and those who underwent the laparoscopic pneumovesical approach were compared. Results During the study period, 52 ureteric reimplantation procedures were analyzed. Among these, 28 and 24 patients underwent surgery using the open and pneumovesical approaches, respectively. The mean operative time did not differ between the groups (143.64 min vs. 128.12 min, P = 0.092). However, the pneumovesical group had a shorter duration of hospital stay (5.08 days vs 7.43 days, P = 0.001) and required less morphine analgesic for pain than did the open group (7.7% vs 32.1%, P = 0.027). No significant differences in the success rates (94.9% vs 92.5%, P = 0.512) or procedure-related complications were noted between the pneumovesical and open techniques. Conclusions The transvesicoscopic Politano-Leadbetter technique with pneumovesicum is safe and effective for ureteric reimplantation and is comparable to the open approach. Open approach n (%) Pneumovesical approach n (%) P value No. of patients 28 24 (2 patients converted to open surgery d/t port displacement) Gender 28 24 0.002 Male 23 (82.1) 9 (37.5) Female 5 (17.9) 15 (62.5) Mean age at operation (y) 5.96 ± 4.19 8.04 ± 4.53 0.115 Side 28 24 0.400 Unilateral 16 (57.1) 11 (45.8) Bilateral 12 (42.9) 13 (54.2) Renal scarring on DMSA 17 (60.7) 14 (58.3) 0.543 VUR grade 28 24 0.776 III 4 (14.3%) 3 (12.5%) IV 9 (32.1%) 10 (41.7%) V 15 (53.6%) 11 (45.8%) DMSA, dimercaptosuccinic acid; VUR, vesicoureteral reflux.
- Published
- 2019
- Full Text
- View/download PDF
9. Enhanced density of states in Li(Fe1−Co )As single crystals near x= 0.06 as implied by transport properties
- Author
-
Bumsung Lee, Seunghyun Khim, Kiyoung Choi, Byung-Jo Jeon, G. R. Stewart, Kee Hoon Kim, Sukho Lee, and Ju-Young Park
- Subjects
Materials science ,Condensed matter physics ,Doping ,Energy Engineering and Power Technology ,Fermi energy ,Electron ,Condensed Matter Physics ,Electronic, Optical and Magnetic Materials ,Residual resistivity ,Electrical resistivity and conductivity ,Density of states ,Superconducting transition temperature ,Electrical and Electronic Engineering ,Phase diagram - Abstract
Single crystals of Li(Fe1−xCox)As (x = 0.00, 0.02, 0.04, 0.06, 0.08 and 0.1) were grown by the Sn-flux method and their resistivity behaviors were investigated. As the Co concentration x increased, the superconducting transition temperature Tc as well as the residual resistivity ratio systematically decreased, indicating a monotonic doping of electron carriers. Upon the analysis of the Fermi-liquid behavior of the resistivity and by using the Kadowaki–Woods relation, the T2 coefficient of the resistivity A and the Sommerfeld coefficient γN were found to increase abruptly near x = 0.06. This is the point in the phase diagram at which the density of states at the Fermi energy (proportional to γN) is expected to be enhanced due to the collapse of the small hole-pockets. This result suggests that the Li(Fe1−xCox)As series at least up to x = 0.08 remain as compensated metals and their transport properties are determined by multi-band effects.
- Published
- 2013
- Full Text
- View/download PDF
10. Correlation of Androgen Deprivation Therapy with Cognitive Dysfunction in Patients with Prostate Cancer: A Nationwide Population-Based Study Using the National Health Insurance Service Database.
- Author
-
Bum Sik Tae, Byung Jo Jeon, Seung Hun Shin, Hoon Choi, Jae Hyun Bae, and Jae Young Park
- Subjects
- *
NATIONAL health insurance , *NATIONAL health services , *COGNITIVE therapy , *PROSTATE cancer patients , *PROPORTIONAL hazards models - Abstract
Purpose The purpose of this study was to evaluate the association of androgen deprivation therapy (ADT) with cognitive dysfunction. Materials and Methods Using the National Health Insurance Service database of the entire Korean adult prostate cancer population (n=236,391), data on ADT and cognitive dysfunction between 2008 and 2015 were analyzed. We excluded patients previously diagnosed with cognitive dysfunction, dementia, or a cerebral event history. We tested the effect of ADT on the risk of cognitive dysfunction using propensity score-matched Cox proportional hazards regression models and Kaplan-Meier survival analysis. Our final cohort comprised of 35,401 individuals with prostate cancer, including 24,567 men (70.6%) who underwent ADT. Results During a mean follow-up period of 4.1 years, 4,741 patients were newly diagnosed with cognitive dysfunction. A statistically significant association was found between ADT and the risk of cognitive dysfunction (hazard ratio, 1.169; p=0.002). Meanwhile, age ( 70 years), diabetes, hypertension, cardiovascular history, and peripheral vascular disease were identified as factors that contribute to the increased risk of cognitive dysfunction. In contrast, the use of statins and aspirin was associated with a lower risk of cognitive dysfunction. Kaplan-Meier analysis demonstrated that patients aged 70 years or older who underwent ADT had the lowest cumulative probability of remaining cognitive dysfunction-free (log-rank p < 0.001). Conclusion Our results revealed an association between the use of ADT for the treatment of prostate cancer and an increased risk of cognitive dysfunction in a nationwide population-based study. This finding should be further evaluated in prospective studies. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.